CA2350071A1 - Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis - Google Patents

Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis Download PDF

Info

Publication number
CA2350071A1
CA2350071A1 CA002350071A CA2350071A CA2350071A1 CA 2350071 A1 CA2350071 A1 CA 2350071A1 CA 002350071 A CA002350071 A CA 002350071A CA 2350071 A CA2350071 A CA 2350071A CA 2350071 A1 CA2350071 A1 CA 2350071A1
Authority
CA
Canada
Prior art keywords
propionyl
carnitine
medicament
acid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002350071A
Other languages
English (en)
French (fr)
Inventor
Menotti Calvani
Claudio Pisano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1998RM000701A external-priority patent/IT1302858B1/it
Priority claimed from PCT/IT1998/000318 external-priority patent/WO2000027386A1/en
Application filed by Individual filed Critical Individual
Publication of CA2350071A1 publication Critical patent/CA2350071A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002350071A 1998-11-11 1999-11-09 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis Abandoned CA2350071A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITRM98A000701 1998-11-11
ITPCT/IT98/00318 1998-11-11
IT1998RM000701A IT1302858B1 (it) 1998-11-11 1998-11-11 Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento avente attivita' antitumorale.
PCT/IT1998/000318 WO2000027386A1 (en) 1998-11-11 1998-11-11 Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
PCT/IT1999/000357 WO2000027387A1 (en) 1998-11-11 1999-11-09 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis

Publications (1)

Publication Number Publication Date
CA2350071A1 true CA2350071A1 (en) 2000-05-18

Family

ID=26330215

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002350071A Abandoned CA2350071A1 (en) 1998-11-11 1999-11-09 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis

Country Status (6)

Country Link
EP (1) EP1128823A1 (https=)
JP (1) JP2002529408A (https=)
KR (1) KR100694004B1 (https=)
AU (1) AU1294600A (https=)
CA (1) CA2350071A1 (https=)
WO (1) WO2000027387A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101006207B1 (ko) * 2008-09-25 2011-01-07 김형호 잡음차단수단을 갖는 헤드셋

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
US5786326A (en) * 1995-02-03 1998-07-28 Horwitz; Lawrence D. Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation
IT1276253B1 (it) * 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
DK0793962T3 (da) * 1996-03-04 2000-05-22 Sigma Tau Ind Farmaceuti Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di

Also Published As

Publication number Publication date
KR100694004B1 (ko) 2007-03-12
JP2002529408A (ja) 2002-09-10
KR20010080379A (ko) 2001-08-22
EP1128823A1 (en) 2001-09-05
AU1294600A (en) 2000-05-29
WO2000027387A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
RU2262933C2 (ru) Медицинские композиции, содержащие аспирин
JP2007534730A (ja) 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物
CN110090304A (zh) 用于治疗动脉粥样硬化的方法
AU2002305952A1 (en) Pharmaceutical combinations
KR20250167640A (ko) 아즈부딘 및 화학요법제를 포함한 항종양 약학적 조성물
KR100244092B1 (ko) L-카르니틴 또는 아실l-카르니틴과 ace-억제제를 함유한 심장혈관질환치료용 약제조성물과 그 치료방법
JP2020508290A (ja) ゴシポールおよびフェンホルミンを有効成分として含む膵臓癌予防および治療用薬学的組成物
US10172914B2 (en) Combination
US20020091092A1 (en) Use of propionyl L-carnitine for the preparation of a medicament capable of inducing apoptosis
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
CA2350071A1 (en) Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
Cheng To market, to market-1995
KR20220034505A (ko) 암의 기원 세포의 사멸용 약학적 조성물
WO2000027386A1 (en) Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
EP0311362A1 (en) Improvements in or relating to pharmaceutical preparations for treating hypertension
EP1448189A2 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
CZ381197A3 (cs) Použití alendronatu pro výrobu farmaceutického prostředku
KR20050116125A (ko) 3,７­디아자비시클로〔３,３,１〕노난 화합물을 포함하는액상의 약제학적 제제 및 항-부정맥발작에 관련한 치료방법
JP2008528704A (ja) 心臓血管系疾患の治療または予防において使用するためのニトロキシド類
AU2002366975B2 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
JP5106403B2 (ja) 透析患者における左室肥大の予防および処置に有用な化合物
KR20070085508A (ko) 지질 농후 플라크의 감소, 안정화 및 파열 방지 방법
WO2005027896A1 (ja) 併用医薬
JP2863534B2 (ja) 医薬組成物
HK40008907A (en) Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead